Tearsheet

Azenta (AZTA)

Market Price (3/18/2026): $22.13 | Market Cap: $1.0 Bil
Sector: Health Care | Industry: Life Sciences Tools & Services

Azenta (AZTA)

Market Price (3/18/2026): $22.13
Market Cap: $1.0 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -35%	Weak multi-year price returns 2Y Excs Rtn is -96%, 3Y Excs Rtn is -120%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -17 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2.8%
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11%	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10%	Weak revenue growth Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.6%
2	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, Precision Medicine, and Automation & Robotics. Themes include Advanced Diagnostics, Show more.		Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10.0%
3			Key risks AZTA key risks include a [1] material weakness in its internal control over financial reporting.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -35%
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11%
2	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, Precision Medicine, and Automation & Robotics. Themes include Advanced Diagnostics, Show more.
3	Weak multi-year price returns 2Y Excs Rtn is -96%, 3Y Excs Rtn is -120%
4	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10%
5	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -17 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2.8%
6	Weak revenue growth Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.6%
7	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10.0%
8	Key risks AZTA key risks include a [1] material weakness in its internal control over financial reporting.

Valuation, Metrics & Events

	3/18/26	2025	2024	2023	2022
Share Price CYE	$22.13	$33.26	$50.00	$65.14	$58.22
Market Cap CYE ($ Bil)	1.0	1.5	2.3	3.7	4.2
Total Debt ($ Bil)	0.1	0.1	0.1	0.1	0.1
Total Cash ($ Bil)	0.4	0.4	0.5	1.0	1.1
Enterprise Value ($ Bil)	0.7	1.6	2.4	3.8	4.3
Valuation Ratios
P/S TTM	1.7	2.6	3.9	7.2	7.1
P/EBIT TTM	-60.3	-90.7	-69.8	-80.5	-87.5
P/E TTM	-17.6	-26.4	-14.2	-193.2	2.0
P/FCF TTM	32.9	49.4	71.4	423.4	-7.3
Sector Ratios
P/S TTM (Sector)	3.7	4.2	3.9	4.2	4.4
P/EBIT TTM (Sector)	-1.7	-1.6	-1.5	-1.4	-1.2
P/E TTM (Sector)	-1.9	-1.8	-1.6	-1.6	-1.2
P/FCF TTM (Sector)	-1.5	-1.5	-1.5	-1.4	-1.6

	3/18/26	2025	2024
Share Price CYE	$22.13	$33.26	$50.00
Market Cap CYE ($ Bil)	1.0	1.5	2.3
Total Debt ($ Bil)	0.1	0.1	0.1
Total Cash ($ Bil)	0.4	0.4	0.5
Enterprise Value ($ Bil)	0.7	1.6	2.4
Valuation Ratios
P/S TTM	1.7	2.6	3.9
P/EBIT TTM	-60.3	-90.7	-69.8
P/E TTM	-17.6	-26.4	-14.2
P/FCF TTM	32.9	49.4	71.4
Sector Ratios
P/S TTM (Sector)	3.7	4.2	3.9
P/EBIT TTM (Sector)	-1.7	-1.6	-1.5
P/E TTM (Sector)	-1.9	-1.8	-1.6
P/FCF TTM (Sector)	-1.5	-1.5	-1.5

	AZTA	S&P 500
REVENUE GROWTH	POOR
Rev LTM ($ Bil)	0.6
Rev Chg Q	0.8%	7.3%
Rev Chg LTM	2.7%	6.6%
Rev Chg 3Y Avg	0.6%	5.7%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	0.1
Net Inc LTM ($ Bil)	-0.1
Op Mgn LTM	-2.8%	18.7%
CFO/Rev LTM	10.6%	20.9%
Net Inc Mgn	-9.7%	12.8%
VALUATION	MODERATE
P/S	1.7	3.2
P/CFO	16.1	15.4
P/FCF	32.9	20.1
P/E	-17.6	24.3
STABILITY	VERY GOOD
Debt/Equity	0.05	0.22
Cash/Assets	0.20	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Samples Supported	1 Billion +	3142024	Link
Employees who are scientists/engineers	1 in 3	3142024	Link
Countries of Operation	>150	3142024	Link
Top Pharma/Biotech Customers	20 of 20	3142024	Link
Sample transactions per month	~1 million	3142024	Link

Upcoming
5/06/2026	Earnings Release	Rev: $148 Mil (E) EPS: $0.10 (E)

Price Chart

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Azenta (AZTA) stock has lost about 40% since 11/30/2025 because of the following key factors:

1. Azenta experienced a significant miss on its Q1 Fiscal 2026 earnings per share (EPS), reporting $0.09 against an anticipated $0.14, representing a 35.71% negative surprise. This shortfall, announced on February 4, 2026, led to an 11.27% drop in the stock's pre-market trading to $32.75.

2. The company faced substantial pressure on its profitability and organic revenue growth during Q1 Fiscal 2026. Gross margin declined by 360 basis points year-over-year to 44.1%, and adjusted EBITDA margin fell by 230 basis points to 8.5%. This was attributed to factors such as lower sales volumes in North America, approximately $2 million in rework costs on Automated Stores projects, and a shift in regional sales mix. Additionally, organic revenue decreased by 1% year-over-year.

Show more

Stock Movement Drivers

Fundamental Drivers

The -38.0% change in AZTA stock from 11/30/2025 to 3/17/2026 was primarily driven by a -38.8% change in the company's P/S Multiple.

(LTM values as of)	11302025	3172026	Change
Stock Price ($)	35.56	22.03	-38.0%
Change Contribution By:
Total Revenues ($ Mil)	586	595	1.5%
P/S Multiple	2.8	1.7	-38.8%
Shares Outstanding (Mil)	46	46	-0.3%
Cumulative Contribution			-38.0%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 3/17/2026

	Return	Correlation
AZTA	-38.0%
Market (SPY)	-1.8%	41.0%
Sector (XLV)	-5.1%	2.5%

Fundamental Drivers

The -27.9% change in AZTA stock from 8/31/2025 to 3/17/2026 was primarily driven by a -28.7% change in the company's P/S Multiple.

(LTM values as of)	8312025	3172026	Change
Stock Price ($)	30.54	22.03	-27.9%
Change Contribution By:
Total Revenues ($ Mil)	586	595	1.5%
P/S Multiple	2.4	1.7	-28.7%
Shares Outstanding (Mil)	46	46	-0.3%
Cumulative Contribution			-27.9%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2025 to 3/17/2026

	Return	Correlation
AZTA	-27.9%
Market (SPY)	4.3%	44.2%
Sector (XLV)	9.4%	33.1%

Fundamental Drivers

The -49.5% change in AZTA stock from 2/28/2025 to 3/17/2026 was primarily driven by a -50.5% change in the company's P/S Multiple.

(LTM values as of)	2282025	3172026	Change
Stock Price ($)	43.62	22.03	-49.5%
Change Contribution By:
Total Revenues ($ Mil)	579	595	2.7%
P/S Multiple	3.4	1.7	-50.5%
Shares Outstanding (Mil)	46	46	-0.7%
Cumulative Contribution			-49.5%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2025 to 3/17/2026

	Return	Correlation
AZTA	-49.5%
Market (SPY)	13.9%	51.6%
Sector (XLV)	1.8%	42.7%

Fundamental Drivers

The -49.8% change in AZTA stock from 2/28/2023 to 3/17/2026 was primarily driven by a -68.3% change in the company's P/S Multiple.

(LTM values as of)	2282023	3172026	Change
Stock Price ($)	43.89	22.03	-49.8%
Change Contribution By:
Total Revenues ($ Mil)	594	595	0.1%
P/S Multiple	5.4	1.7	-68.3%
Shares Outstanding (Mil)	73	46	57.9%
Cumulative Contribution			-49.8%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2023 to 3/17/2026

	Return	Correlation
AZTA	-49.8%
Market (SPY)	75.6%	41.7%
Sector (XLV)	23.1%	35.3%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
AZTA Return	53%	-44%	12%	-23%	-33%	-37%	-69%
Peers Return	37%	-23%	-9%	-1%	5%	-11%	-11%
S&P 500 Return	27%	-19%	24%	23%	16%	-2%	78%
Monthly Win Rates [3]
AZTA Win Rate	50%	33%	50%	42%	50%	33%
Peers Win Rate	78%	35%	43%	48%	52%	20%
S&P 500 Win Rate	75%	42%	67%	75%	67%	33%
Max Drawdowns [4]
AZTA Max Drawdown	-2%	-63%	-37%	-38%	-50%	-37%
Peers Max Drawdown	-4%	-35%	-29%	-12%	-26%	-14%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-3%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMO, DHR, ILMN, A, LH.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/17/2026 (YTD)

How Low Can It Go

Unique Key	Event	AZTA	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-70.6%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	240.6%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-48.6%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	94.5%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	104 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-41.4%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	70.5%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	133 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-87.1%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	673.6%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	2,996 days	1,480 days

Compare to TMO, DHR, ILMN, A, LH

In The Past

Azenta's stock fell -70.6% during the 2022 Inflation Shock from a high on 11/8/2021. A -70.6% loss requires a 240.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Azenta (AZTA)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Azenta, Inc. provides manufacturing automation solutions for the semiconductor industry, and life science sample-based services and solutions for the life sciences market worldwide. The company operates in two segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated ultra-cold storage systems and consumables, including racks, tubes, caps, plates, and foils; instruments, such as labeling, bar coding, capping, de-capping, auditing, sealing, peeling, piercing tubes, and plates. The Life Sciences Services segment offers genomic services and sample repository solutions, including on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting; and informatics provides sample intelligence software solutions, which support laboratory workflow scheduling for life science tools and instrument work cells, sample, inventory and logistics, environmental and temperature monitoring, clinical trial and consent management, and planning, data management, virtualization and visualization of sample collections. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.

AI Analysis | Feedback

Here are 1-3 brief analogies to describe Azenta:

Like **Applied Materials** for semiconductor manufacturing automation.
The **Amazon Web Services (AWS)** for managing physical and digital assets in high-tech life science labs.

AI Analysis | Feedback

```html

Automated Ultra-Cold Storage Systems: Advanced systems designed for the precise and secure ultra-cold storage of biological samples.
Life Sciences Consumables: Essential items like racks, tubes, caps, plates, and foils used in sample management and storage.
Life Sciences Instruments: Devices for automating tasks such as labeling, capping, de-capping, and auditing of tubes and plates.
Genomic Services: Specialized services focused on genomic analysis and related solutions for the life sciences market.
Sample Repository Solutions: Comprehensive services including sample storage (on-site and off-site), cold chain logistics, and biospecimen procurement.
Sample Intelligence Software (Informatics): Software solutions that support laboratory workflow scheduling, sample inventory, logistics, and data management for life science operations.

```

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

John Marotta, President & Chief Executive Officer

Mr. Marotta joined Azenta Life Sciences in September 2024 as President and CEO. He brings two decades of experience leading global companies in life sciences, medical devices, and diagnostics. Prior to Azenta, Mr. Marotta served as Executive in Residence of Patient Square Capital, a leading healthcare investment firm. He previously held the roles of CEO and President of PHC Holdings Corporation (formerly Panasonic Health Care), a diversified global life sciences, diagnostics, and medical device company, where he oversaw its global revenue growth and led its IPO from owners KKR Capital. He also held various senior executive positions at Danaher Corporation, Envista Holdings Corporation, and Cardinal Health, Inc., where he was involved in significant value-creating transactions.

Lawrence Lin, Executive Vice President & Chief Financial Officer

Mr. Lin joined Azenta in November 2024 as Executive Vice President and Chief Financial Officer, bringing over twenty years of finance experience. Before joining Azenta, Mr. Lin was Chief Financial Officer at GeoStabilization International LLC, a privately held industrial company. He also served as Senior Vice President of Finance Operations at PHC Holdings Corporation. His prior roles include Vice President of Finance for North America (CFO) and Global Functions at LivaNova, a global medical technology company, and Vice President of Finance Operations at KaVo Kerr, which was part of Danaher before being spun off as Envista.

Dr. Ginger Zhou, Senior Vice President, President GENEWIZ

Dr. Zhou serves as the Senior Vice President and President of GENEWIZ, an Azenta Life Sciences brand.

Olga Pirogova, Senior Vice President & Chief Human Resources Officer

Mrs. Pirogova joined Azenta Life Sciences in August 2023. She is responsible for developing and executing Azenta's human resources strategy. Prior to Azenta, Ms. Pirogova served as CHRO at Speedcast, a global satellite communications service provider.

Ephraim Starr, Senior Vice President, General Counsel & Corporate Secretary

Mr. Starr holds the position of Senior Vice President, General Counsel & Corporate Secretary at Azenta Life Sciences.

AI Analysis | Feedback

```html

Exposure to Semiconductor Industry Cyclicality: Azenta provides manufacturing automation solutions for the semiconductor industry. This sector is known for its cyclical nature and sensitivity to global economic conditions, which can lead to fluctuations in demand for Azenta's automation products and services.
Intense Competition and Rapid Technological Change in Life Sciences: Azenta operates in the highly competitive life sciences market, offering products like automated storage systems and services such as genomics and sample management. The need to continually innovate and adapt to rapid technological advancements and evolving customer needs, coupled with competition from established players and new entrants, poses a significant risk to market share and profitability.
Data Security, Privacy, and Regulatory Compliance in Sample Management: As a provider of sample repository solutions, cold chain logistics, biospecimen procurement, and sample intelligence software, Azenta handles sensitive biological samples and associated data. Risks include potential data breaches, non-compliance with evolving data privacy regulations (e.g., HIPAA, GDPR-like regulations), and the operational and reputational damage that could result from such incidents.

```

AI Analysis | Feedback

null

AI Analysis | Feedback

Azenta, Inc. (AZTA) operates primarily within the life sciences market, providing a range of products and services. The addressable markets for their main offerings are detailed below:

Genomic Services: The global genomics services market was valued at approximately USD 8.5 billion in 2024 and is projected to grow to around USD 25 billion by 2034, exhibiting a compound annual growth rate (CAGR) of over 11.5% from 2025 to 2034. North America is a significant region within this market, with the U.S. market alone valued at USD 4.3 billion in 2024 and expected to reach USD 9.6 billion by 2034.
Sample Repository Solutions / Biobanking: The global biobanks market size was estimated at USD 86.82 billion in 2025 and is anticipated to reach USD 160.54 billion by 2033, growing at a CAGR of 8.11% from 2026 to 2033. Europe held the largest share of this market in 2025, while the biobank industry in the U.S. is expected to grow significantly.
Automated Ultra-Cold Storage Systems: The global automated sample storage systems market, which includes automated ultra-cold storage, was valued at approximately USD 1.5 billion in 2024 and is projected to reach around USD 4.6 billion by 2034, with a CAGR of 11.8% during the forecast period from 2025 to 2034. North America led this market in 2024, holding over a 38.5% share. Automated ultra-cold storage at -80 °C accounted for 51.1% of the automated sample storage systems market in 2024.
Laboratory Automation Instruments: The global laboratory automation market size was valued at USD 9.2 billion in 2025 and is projected to grow to USD 20.71 billion by 2034, exhibiting a CAGR of 9.43% during the forecast period. North America holds approximately 37% market share in the global laboratory automation market.
Sample Intelligence Software Solutions (Informatics): The global laboratory sample management software market size was estimated at USD 1.85 billion in 2025 and is expected to reach USD 4.74 billion by 2032, with a CAGR of 14.38%.

AI Analysis | Feedback

Azenta (NASDAQ: AZTA) is expected to drive future revenue growth over the next two to three years through several key initiatives within its core life sciences segments.

One primary driver is the anticipated organic revenue growth in its core Sample Management Solutions (SMS) and Multiomics segments. The company has provided guidance for 3% to 5% organic revenue growth for fiscal years 2025 and 2026. This growth is expected to be fueled by mid-single-digit growth in Sample Management Solutions, driven by consumables, instruments, and clinical cryogenic stores, while the Multiomics segment is projected for low-single-digit growth, with Next-Generation Sequencing (NGS) services being a strong contributor.

Another significant driver is the expansion of its biorepository presence and services, both organically and through strategic mergers and acquisitions. Azenta plans to grow its biorepository footprint in Europe and the U.K. through M&A, exemplified by the acquisition of UK Biocentre. This expansion aims to scale automated biobanking operations and enhance the company's partnerships with government, academic, and pharmaceutical/biotech customers, leading to increased sample processing and storage volumes.

Furthermore, investments in new technologies and automated solutions, alongside the regionalization of gene synthesis, are expected to contribute to revenue growth. Azenta is focusing on regionalizing gene synthesis capabilities in the U.S. and Europe, partly due to BIOSECURE concerns. The company continues to invest in innovative technology and automated solutions, emphasizing its identity as an "automated solutions business" rather than solely a freezer business.

Finally, the company anticipates new product launches in 2027 and 2028, which will open up fresh avenues for revenue generation and sustain long-term growth.

AI Analysis | Feedback

Share Repurchases

Azenta authorized a $250 million share repurchase program in December 2025, set to continue until December 31, 2028.
In November 2022, the company authorized a $1.5 billion share repurchase program, with an intention to repurchase at least $1 billion in common stock over the subsequent year, including a $500 million accelerated share repurchase program.

Share Issuance

Proceeds from the issuance of common stock were $2.77 million in fiscal year 2025.
Proceeds from the issuance of common stock were $3.279 million in fiscal year 2024.

Outbound Investments

Azenta acquired UK Biocentre Limited in March 2026 for GBP 20.5 million (net of cash and including contingent consideration), expanding its biorepository capabilities and establishing a European operational hub.
The company divested its B Medical Systems business for $63 million in December 2025, with the sale expected to close by March 31, 2026, as part of a portfolio simplification strategy.
In February 2023, Azenta acquired Ziath Ltd., a provider of 2D barcode readers for life sciences applications.

Capital Expenditures

Capital expenditures totaled $34 million for the full fiscal year 2025.
For the first quarter of fiscal year 2026 (ended December 31, 2025), capital expenditures were $6 million.
The company's capital allocation strategy includes investing in high-value R&D, sales & marketing, and high-margin, high Return on Invested Capital (ROIC) parts of the business.

Interactive Breakdown

null

null

Better Bets vs. Azenta (AZTA)

Amazon.com

NVDA (2.7%)

NVIDIA

Best Bets in Health Care

What You Pay

P/EBIT (Value for AZTA: -60.1x)

RPRX (12.1x)

Royalty Pharma

VEEV (35.7x)

Veeva Systems

DOCS (19.6x)

Doximity

HALO (15.8x)

Halozyme Therapeutics

UTHR (13.5x)

United Therapeutics

CPRX (11.1x)

Catalyst Pharmaceuticals

BMY (10.8x)

Bristol-Myers Squibb

RMD (18.5x)

ResMed

PBH (9.7x)

Prestige Consumer Healthcare

JNJ (17.1x)

Johnson & Johnson

P/E (Value for AZTA: -17.5x)

RPRX (25.6x)

Royalty Pharma

VEEV (35.6x)

Veeva Systems

DOCS (19.5x)

Doximity

HALO (24.2x)

Halozyme Therapeutics

UTHR (17.6x)

United Therapeutics

CPRX (13.4x)

Catalyst Pharmaceuticals

BMY (17.2x)

Bristol-Myers Squibb

RMD (22.9x)

ResMed

PBH (16.0x)

Prestige Consumer Healthcare

JNJ (21.4x)

Johnson & Johnson

What You Get

Rev Chg 3Y Avg (Value for AZTA: 0.6%)

RPRX (2.1%)

Royalty Pharma

VEEV (14.1%)

Veeva Systems

DOCS (16.7%)

Doximity

HALO (28.5%)

Halozyme Therapeutics

UTHR (18.1%)

United Therapeutics

CPRX (43.1%)

Catalyst Pharmaceuticals

BMY (1.5%)

Bristol-Myers Squibb

RMD (12.9%)

ResMed

PBH (-0.1%)

Prestige Consumer Healthcare

JNJ (2.6%)

Johnson & Johnson

Rev Chg LTM (Value for AZTA: 2.7%)

RPRX (5.1%)

Royalty Pharma

VEEV (16.0%)

Veeva Systems

DOCS (15.9%)

Doximity

HALO (37.6%)

Halozyme Therapeutics

UTHR (10.6%)

United Therapeutics

CPRX (19.8%)

Catalyst Pharmaceuticals

BMY (-0.2%)

Bristol-Myers Squibb

RMD (9.6%)

ResMed

PBH (-1.3%)

Prestige Consumer Healthcare

JNJ (6.0%)

Johnson & Johnson

Rev Chg Q (Value for AZTA: 0.8%)

RPRX (4.8%)

Royalty Pharma

VEEV (16.0%)

Veeva Systems

DOCS (9.8%)

Doximity

HALO (51.6%)

Halozyme Therapeutics

UTHR (7.4%)

United Therapeutics

CPRX (7.6%)

Catalyst Pharmaceuticals

BMY (1.3%)

Bristol-Myers Squibb

RMD (11.0%)

ResMed

PBH (-2.4%)

Prestige Consumer Healthcare

JNJ (9.1%)

Johnson & Johnson

FCF/Rev 3Y Avg (Value for AZTA: 4.1%)

RPRX (118.0%)

Royalty Pharma

VEEV (41.8%)

Veeva Systems

DOCS (41.6%)

Doximity

HALO (38.8%)

Halozyme Therapeutics

UTHR (34.1%)

United Therapeutics

CPRX (33.2%)

Catalyst Pharmaceuticals

BMY (27.9%)

Bristol-Myers Squibb

RMD (27.3%)

ResMed

PBH (22.3%)

Prestige Consumer Healthcare

JNJ (20.6%)

Johnson & Johnson

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	Azenta Stock Shares Sink 23% In A Day, Now Is Not The Time To Buy The Stock	02/05/2026
2	Can Azenta Stock Recover If Markets Fall?	02/05/2026
3	Azenta Earnings Notes	12/16/2025
4	Is Azenta Stock Outperforming Its Rivals?	11/22/2025
5	Why Azenta Stock Moved: AZTA Stock Has Lost 67% Since 2021 Fiscal End, Primarily Due To Unfavorable Change In Price To Sales Multiple (P/S)	08/08/2025
6	AZTA Dip Buy Analysis	07/10/2025
7	Azenta (AZTA) Valuation Ratios Comparison	05/15/2025
8	Azenta Total Shareholder Return (TSR): -40.7% in 2025 and -12.4% 3-yr compounded annual returns (above peer average)	03/07/2025
9	Azenta (AZTA) Operating Cash Flow Comparison	02/17/2025
10	Azenta (AZTA) Net Income Comparison	02/15/2025
11	ARTICLES
12	Azenta Stock To $20?	02/05/2026
13	Azenta Stock Drop Looks Sharp, But How Deep Can It Go?	02/05/2026
14	Azenta Stock To $25?	11/22/2025

	Title
0	DASHBOARDS
1	Azenta Stock Shares Sink 23% In A Day, Now Is Not The Time To Buy The Stock
2	Can Azenta Stock Recover If Markets Fall?
3	Azenta Earnings Notes
4	Is Azenta Stock Outperforming Its Rivals?
5	Why Azenta Stock Moved: AZTA Stock Has Lost 67% Since 2021 Fiscal End, Primarily Due To Unfavorable Change In Price To Sales Multiple (P/S)
6	AZTA Dip Buy Analysis
7	Azenta (AZTA) Valuation Ratios Comparison
8	Azenta Total Shareholder Return (TSR): -40.7% in 2025 and -12.4% 3-yr compounded annual returns (above peer average)
9	Azenta (AZTA) Operating Cash Flow Comparison
10	Azenta (AZTA) Net Income Comparison
11	ARTICLES
12	Azenta Stock To $20?
13	Azenta Stock Drop Looks Sharp, But How Deep Can It Go?
14	Azenta Stock To $25?

Trade Ideas

Select ideas related to AZTA.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
QDEL_2282026_Insider_Buying_45D_2Buy_200K	02282026	QDEL	QuidelOrtho	Insider	Insider Buys 45DStrong Insider Buying Companies with multiple insider buys in the last 45 days	0.0%	0.0%	0.0%
CHE_2272026_Dip_Buyer_FCFYield	02272026	CHE	Chemed	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	0.0%	0.0%	0.0%
LLY_2272026_Monopoly_xInd_xCD_Getting_Cheaper	02272026	LLY	Eli Lilly	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	0.0%	0.0%	0.0%
HAE_2202026_Dip_Buyer_FCFYield	02202026	HAE	Haemonetics	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	3.5%	3.5%	0.0%
IQV_2132026_Dip_Buyer_ValueBuy	02132026	IQV	IQVIA	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	7.1%	7.1%	-3.0%
AZTA_11302024_Insider_Buying_45D_2Buy_200K	11302024	AZTA	Azenta	Insider	Insider Buys 45DStrong Insider Buying Companies with multiple insider buys in the last 45 days	-42.2%	-23.0%	-45.8%
AZTA_8312022_Insider_Buying_45D_2Buy_200K	08312022	AZTA	Azenta	Insider	Insider Buys 45DStrong Insider Buying Companies with multiple insider buys in the last 45 days	-17.1%	7.1%	-30.8%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
BW	Babcock & Wilcox Enterprises	1.5	26.9%	135.0%
TROX	Tronox	1.2	17.4%	89.4%
RHLD	Resolute Management	1.2	17.1%	-29.4%
LMND	Lemonade	5.0	15.8%	-6.1%
BTDR	Bitdeer Technologies	1.9	12.8%	-17.5%
ICHR	Ichor	1.6	11.8%	158.4%
SEI	Solaris Energy Infrastructure	2.8	10.9%	37.8%
RKLB	Rocket Lab	41.6	10.2%	12.7%
PL	Planet Labs PBC	8.4	10.1%	37.3%
ATLC	Atlanticus	0.8	10.1%	-19.6%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
MVST	Microvast	0.5	-34.2%	-45.7%
CTMX	CytomX Therapeutics	0.9	-19.3%	27.9%
ASO	Academy Sports and Outdoors	3.3	-11.7%	-0.1%
SMTC	Semtech	6.9	-11.0%	7.5%
CRDO	Credo Technology	18.2	-11.0%	-27.7%
FRPT	Freshpet	3.3	-10.5%	10.7%
CWCO	Consolidated Water	0.5	-9.4%	-10.8%
OLMA	Olema Pharmaceuticals	1.3	-9.3%	-39.8%
AXTI	AXT	1.9	-8.3%	171.3%
AAOI	Applied Optoelectronics	5.5	-8.2%	147.6%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
LWLG	Lightwave Logic	1.0	68.8%	127.2%
WOOF	Petco Health and Wellness	0.9	45.1%	20.3%
OCGN	Ocugen	0.7	38.4%	81.5%
BLDP	Ballard Power Systems	0.8	36.0%	5.5%
FLY	Firefly Aerospace	2.3	26.8%	9.9%
DOCN	DigitalOcean	7.1	25.1%	61.2%
APEI	American Public Education	1.0	23.0%	48.1%
ORKA	Oruka Therapeutics	1.8	22.6%	36.3%
HPK	HighPeak Energy	0.8	21.8%	41.4%
BTDR	Bitdeer Technologies	1.9	21.7%	-17.5%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
AAOI	Applied Optoelectronics	5.5	-28.4%	147.6%
MVST	Microvast	0.5	-27.3%	-45.7%
FWRD	Forward Air	0.5	-25.4%	-34.2%
IOVA	Iovance Biotherapeutics	1.4	-25.2%	42.5%
NTSK	Netskope	2.3	-21.1%	-46.0%
BETA	BETA Technologies	3.4	-21.1%	-44.1%
NG	Novagold Resources	4.0	-20.9%	4.5%
THM	International Tower Hill Mines	0.5	-20.9%	28.5%
ULTA	Ulta Beauty	23.4	-19.2%	-13.5%
CDRE	Cadre	1.3	-18.9%	-19.0%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
CRCL	Circle Internet	30.4	120.4%	66.8%
LWLG	Lightwave Logic	1.0	110.9%	127.2%
AMPX	Amprius Technologies	2.5	94.4%	145.6%
AAOI	Applied Optoelectronics	5.5	94.2%	147.6%
SOC	Sable Offshore	1.7	93.8%	91.0%
DAWN	Day One Biopharmaceuticals	2.2	87.6%	128.4%
AXTI	AXT	1.9	83.0%	171.3%
OCGN	Ocugen	0.7	73.8%	81.5%
ACLX	Arcellx	6.5	67.2%	75.6%
DNTH	Dianthus Therapeutics	3.0	66.5%	91.5%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
MNKD	MannKind	0.8	-51.8%	-51.9%
GRAL	GRAIL	1.7	-51.4%	-44.7%
EOSE	Eos Energy Enterprises	1.5	-49.2%	-50.8%
CWH	Camping World	0.4	-45.5%	-35.7%
VITL	Vital Farms	0.7	-44.7%	-50.8%
PSIX	Power Solutions International	1.3	-43.8%	-2.8%
GO	Grocery Outlet	0.6	-43.1%	-42.1%
MATV	Mativ	0.5	-40.8%	-27.9%
SHLS	Shoals Technologies	1.0	-39.7%	-27.4%
FWRD	Forward Air	0.5	-38.6%	-34.2%

Peer Comparisons

Peers to compare with:

Financials

	AZTA	TMO	DHR	ILMN	A	LH	Median
Name	Azenta	Thermo F.	Danaher	Illumina	Agilent .	Labcorp
Mkt Price	22.03	472.71	195.21	120.84	112.75	270.62	158.03
Mkt Cap	1.0	176.8	138.1	18.4	31.9	22.4	27.1
Rev LTM	595	44,555	24,568	4,343	7,065	13,952	10,508
Op Inc LTM	-17	8,109	4,690	816	1,456	1,516	1,486
FCF LTM	31	6,293	5,260	931	993	1,206	1,100
FCF 3Y Avg	24	6,829	5,446	641	1,318	1,059	1,188
CFO LTM	63	7,818	6,416	1,079	1,396	1,640	1,518
CFO 3Y Avg	59	8,297	6,756	798	1,685	1,518	1,601

Growth & Margins

	AZTA	TMO	DHR	ILMN	A	LH	Median
Name	Azenta	Thermo F.	Danaher	Illumina	Agilent .	Labcorp
Rev Chg LTM	2.7%	3.9%	2.9%	-0.7%	8.1%	7.2%	3.4%
Rev Chg 3Y Avg	0.6%	-0.2%	-2.5%	-1.8%	0.8%	3.5%	0.2%
Rev Chg Q	0.8%	7.2%	4.6%	5.0%	7.0%	5.6%	5.3%
QoQ Delta Rev Chg LTM	0.2%	1.9%	1.2%	1.3%	1.7%	1.4%	1.3%
Op Mgn LTM	-2.8%	18.2%	19.1%	18.8%	20.6%	10.9%	18.5%
Op Mgn 3Y Avg	-5.8%	17.8%	20.4%	9.0%	20.9%	9.6%	13.7%
QoQ Delta Op Mgn LTM	0.4%	-0.2%	0.1%	0.2%	-0.7%	1.0%	0.1%
CFO/Rev LTM	10.6%	17.5%	26.1%	24.8%	19.8%	11.8%	18.7%
CFO/Rev 3Y Avg	10.3%	19.1%	28.0%	18.2%	25.0%	11.6%	18.7%
FCF/Rev LTM	5.2%	14.1%	21.4%	21.4%	14.1%	8.6%	14.1%
FCF/Rev 3Y Avg	4.1%	15.7%	22.6%	14.6%	19.5%	8.1%	15.2%

Valuation

	AZTA	TMO	DHR	ILMN	A	LH	Median
Name	Azenta	Thermo F.	Danaher	Illumina	Agilent .	Labcorp
Mkt Cap	1.0	176.8	138.1	18.4	31.9	22.4	27.1
P/S	1.7	4.0	5.6	4.2	4.5	1.6	4.1
P/EBIT	-60.1	20.3	30.7	15.5	20.7	16.8	18.5
P/E	-17.5	26.4	38.2	21.6	24.7	25.5	25.1
P/CFO	16.0	22.6	21.5	17.0	22.9	13.6	19.3
Total Yield	-5.7%	3.8%	2.6%	4.6%	4.9%	5.0%	4.2%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.9%	1.1%	0.0%
FCF Yield 3Y Avg	1.2%	3.3%	3.3%	3.1%	3.4%	5.4%	3.3%
D/E	0.1	0.2	0.1	0.1	0.1	0.3	0.1
Net D/E	-0.4	0.2	0.1	0.1	0.1	0.3	0.1

Returns

	AZTA	TMO	DHR	ILMN	A	LH	Median
Name	Azenta	Thermo F.	Danaher	Illumina	Agilent .	Labcorp
1M Rtn	-23.0%	-6.3%	-8.2%	3.5%	-10.4%	-4.0%	-7.2%
3M Rtn	-35.8%	-17.0%	-13.0%	-8.1%	-18.9%	5.1%	-15.0%
6M Rtn	-28.0%	-1.5%	2.8%	19.1%	-11.0%	-0.8%	-1.1%
12M Rtn	-41.2%	-8.7%	-7.6%	41.0%	-7.2%	13.8%	-7.4%
3Y Rtn	-44.2%	-12.8%	-8.2%	-44.6%	-13.4%	29.9%	-13.1%
1M Excs Rtn	-21.3%	-4.5%	-6.4%	5.2%	-8.6%	-2.3%	-5.5%
3M Excs Rtn	-36.0%	-15.6%	-12.0%	-8.8%	-17.5%	4.3%	-13.8%
6M Excs Rtn	-27.9%	-1.7%	2.3%	18.2%	-11.4%	-2.7%	-2.2%
12M Excs Rtn	-59.2%	-28.2%	-25.9%	22.1%	-25.3%	-4.9%	-25.6%
3Y Excs Rtn	-119.9%	-86.1%	-80.9%	-109.8%	-89.0%	-49.5%	-87.6%

FDIC Bank Data

$ Mil \| FY: 9/30	LTM	2025	2024	2023	2022	2021	2020
Period End	12/31/2025	9/30/2025	9/30/2024	9/30/2023	9/30/2022	9/30/2021	9/30/2020
Filing Date	2/5/2026	12/4/2025	11/27/2024	11/21/2023	11/25/2022	11/24/2021	11/18/2020
Key Financials
Total Revenue	595	594	573	551	555	514	389
EBITDA	40	40	51	29	30	18	28
Operating Income	-17	-22	-40	-57	-23	-31	-36
Net Income	-58	-56	-165	-15	2,133	111	65
EPS	-1.34	-1.22	-3.10	-0.22	28.48	1.49	0.88
Growth Rates
Total Revenue Growth	2.7%	3.6%	4.0%	-0.7%	8.1%	32.2%	16.3%
EBITDA Growth	-26.5%	-22.3%	76.0%	-4.5%	64.6%	-34.6%	488.1%
Operating Income Growth	48.4%	45.6%	29.7%	-141.9%	23.7%	14.5%	22.0%
Net Income Growth	63.9%	66.2%	-1026.7%	-100.7%	1825.9%	70.8%	-85.2%
Margins
EBITDA Margin	6.7%	6.7%	8.9%	5.2%	5.5%	3.6%	7.2%
Operating Income Margin	-2.8%	-3.6%	-7.0%	-10.3%	-4.2%	-6.0%	-9.2%
Net Income Margin	-9.7%	-9.4%	-28.8%	-2.7%	384.0%	21.6%	16.7%
Cash & Debt
Total Cash	410	341	431	1,018	1,570	228	251
Total Debt	54	51	57	60	49	95	69
Net Debt / (Cash)	-355	-290	-375	-957	-1,521	-133	-181
Cash Flows
Net Cash from Operations	63	72	50	6	-466	150	38
Free Cash from Operations	31	38	12	-34	-543	97	-2
Returns to Shareholders
Dividends	0	-0	-0	-0	7	30	30
Share Repurchases	-0	-0	662	839	-0	-0	-0

$ Mil \| FY: 9/30	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2
Period End	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023
Filing Date	2/5/2026	12/4/2025	8/6/2025	5/9/2025	2/10/2025	11/27/2024	8/6/2024	5/9/2024	2/8/2024	11/21/2023	8/9/2023	5/10/2023
Key Financials Quarterly
Total Revenue	149	159	144	143	147	151	144	136	142	59	166	148
Ebitda	8	16	15	1	10	21	17	6	6	37	5	-7
Operating Income	-6	2	0	-13	-8	-3	-5	-16	-15	15	-16	-29
Net Income	-15	51	-53	-40	-11	-6	-7	-137	-16	3	-1	-5
EPS	-0.34	1.03	-1.15	-0.88	-0.25	-0.11	-0.12	-2.47	-0.28	0.06	-0.02	-0.07
Key Financials TTM
Total Revenue TTM	595	594	586	586	579	573	481	503	515	551	630	597
Ebitda TTM	40	42	47	49	54	51	67	54	41	29	-14	-4
Operating Income TTM	-17	-19	-24	-29	-33	-40	-22	-33	-46	-57	-86	-74
Net Income TTM	-58	-53	-110	-64	-160	-165	-156	-151	-19	-15	-38	-46
Growth Rates Quarterly
Total Revenue Growth	0.8%	5.2%	-0.2%	5.2%	4.0%	157.1%	-13.0%	-8.1%	-20.5%	-57.3%	25.0%	2.0%
EBITDA Growth	-23.2%	-22.7%	-14.6%	-77.8%	53.4%	-42.9%	254.5%	193.4%	206.0%	701.2%	-67.9%	-168.8%
Operating Income Growth	26.3%	162.0%	100.7%	22.0%	46.5%	-119.6%	67.1%	43.7%	41.0%	202.6%	-225.4%	-618.1%
Net Income Growth	-40.4%	990.2%	-702.3%	70.4%	30.1%	-290.6%	-347.8%	-2678.2%	-40.0%	114.4%	84.6%	-100.2%
Margins Quarterly
EBITDA Margin	5.1%	10.2%	10.3%	1.0%	6.7%	13.9%	12.0%	4.6%	4.5%	62.5%	2.9%	-4.5%
Operating Income Margin	-4.1%	1.1%	0.0%	-8.8%	-5.6%	-1.9%	-3.7%	-11.8%	-10.9%	24.9%	-9.9%	-19.3%
Net Income Margin	-10.4%	32.0%	-36.7%	-28.2%	-7.5%	-3.8%	-4.6%	-100.4%	-11.1%	5.1%	-0.9%	-3.3%
Cash & Debt
Total Cash	410	341	319	328	463	431	596	822	984	1,018	1,124	1,181
Total Debt	54	51	53	54	54	57	71	74	66	60	62	57
Net Debt / (Cash)	-355	-290	-266	-275	-409	-375	-524	-748	-918	-957	-1,062	-1,124
Cash Flows Quarterly
FCF from Operations	21	2	26	14	30	18	10	9	14	28	17	-12
Cash Flows TTM
FCF from Operations TTM	63	72	88	72	66	50	60	67	47	6	-13	-449
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	249	226	74	113	166	172	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-	-	-	-	-	-	-	-	-	-	-	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-	-	-	-	-	-	-	-	-	-	-	-

Segment Financials

Assets by Segment

$ Mil	2025	2024	2023	2022	2021
Sample Management Solutions	859	676
Cash and cash equivalents, restricted cash and marketable securities	491	1,134	2,305	244	306
Multiomics	463	534
Assets held for sale	263			495
General corporate assets	24
Deferred tax assets	1	1	1	10	5
B Medical Systems		512
Other assets		29	181	11
Life Sciences Products			379	279	214
Life Sciences Services			850	780	738
Brooks Semiconductor Solutions Group					296
Total	2,100	2,886	3,716	1,820	1,559

Price Behavior

Price Behavior

Market Price	$22.03
Market Cap ($ Bil)	1.0
First Trading Date	12/29/2006
Distance from 52W High	-46.3%
	50 Days	200 Days
DMA Price	$31.61	$31.52
DMA Trend	indeterminate	down
Distance from DMA	-30.3%	-30.1%
	3M	1YR
Volatility	62.1%	59.5%
Downside Capture	335.81	252.68
Upside Capture	97.48	151.76
Correlation (SPY)	38.0%	52.5%

AZTA Betas & Captures as of 2/28/2026

	1M	2M	3M	6M	1Y	3Y
Beta	2.95	2.47	2.36	2.24	1.60	1.36
Up Beta	0.81	1.74	1.71	2.73	1.23	1.30
Down Beta	3.64	2.19	2.40	1.88	1.59	1.42
Up Capture	124%	196%	178%	227%	221%	135%
Bmk +ve Days	9	20	31	70	142	431
Stock +ve Days	8	20	29	59	116	364
Down Capture	510%	343%	296%	212%	154%	110%
Bmk -ve Days	12	21	30	54	109	320
Stock -ve Days	13	21	31	64	133	385

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AZTA
AZTA	-37.5%	59.4%	-0.56	-
Sector ETF (XLV)	4.6%	17.5%	0.11	42.7%
Equity (SPY)	20.3%	18.8%	0.85	52.4%
Gold (GLD)	68.2%	26.2%	1.97	7.1%
Commodities (DBC)	19.1%	17.3%	0.89	22.2%
Real Estate (VNQ)	7.6%	16.1%	0.27	37.7%
Bitcoin (BTCUSD)	-10.5%	44.3%	-0.12	30.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AZTA
AZTA	-22.0%	51.0%	-0.30	-
Sector ETF (XLV)	7.3%	14.5%	0.32	39.2%
Equity (SPY)	13.0%	17.0%	0.60	50.4%
Gold (GLD)	23.4%	17.2%	1.11	9.5%
Commodities (DBC)	11.0%	19.0%	0.47	12.4%
Real Estate (VNQ)	4.8%	18.8%	0.16	40.2%
Bitcoin (BTCUSD)	6.1%	56.7%	0.33	21.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AZTA
AZTA	9.7%	50.2%	0.38	-
Sector ETF (XLV)	10.2%	16.5%	0.50	42.7%
Equity (SPY)	14.8%	17.9%	0.71	54.0%
Gold (GLD)	14.4%	15.6%	0.76	5.7%
Commodities (DBC)	8.5%	17.6%	0.40	16.1%
Real Estate (VNQ)	5.8%	20.7%	0.24	38.8%
Bitcoin (BTCUSD)	68.3%	66.8%	1.07	15.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	2272026
Short Interest: Shares Quantity	4.7 Mil
Short Interest: % Change Since 2152026	-8.0%
Average Daily Volume	0.6 Mil
Days-to-Cover Short Interest	8.0 days
Basic Shares Quantity	45.9 Mil
Short % of Basic Shares	10.2%

Returns Analyses

	Title
0	Can Azenta Stock Recover If Markets Fall?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
2/4/2026	-22.8%	-18.7%	-32.8%
11/21/2025	16.3%	16.2%	15.7%
8/5/2025	-17.0%	-13.7%	-9.4%
5/7/2025	-0.6%	9.8%	11.3%
1/30/2025	0.3%	0.2%	-23.7%
11/12/2024	-3.2%	-11.0%	-0.1%
8/6/2024	-8.9%	-6.9%	-19.0%
5/8/2024	-2.9%	-4.6%	-0.2%
...
SUMMARY STATS
# Positive	10	12	12
# Negative	14	12	12
Median Positive	13.0%	15.7%	11.0%
Median Negative	-7.0%	-7.7%	-11.3%
Max Positive	21.8%	22.3%	32.4%
Max Negative	-22.8%	-18.7%	-32.8%

	Forward Returns
2/4/2026	-22.8%	-18.7%	-32.8%
11/21/2025	16.3%	16.2%	15.7%
8/5/2025	-17.0%	-13.7%	-9.4%
5/7/2025	-0.6%	9.8%	11.3%
1/30/2025	0.3%	0.2%	-23.7%
11/12/2024	-3.2%	-11.0%	-0.1%
8/6/2024	-8.9%	-6.9%	-19.0%
5/8/2024	-2.9%	-4.6%	-0.2%
2/7/2024	-1.6%	0.9%	0.5%
11/13/2023	13.9%	17.2%	26.5%
8/8/2023	20.3%	18.7%	9.7%
5/9/2023	-18.9%	-11.5%	1.1%
2/8/2023	-18.3%	-16.8%	-27.5%
11/14/2022	21.8%	22.3%	32.4%
8/9/2022	-3.1%	-2.8%	-17.7%
5/9/2022	5.6%	15.3%	19.8%
2/8/2022	3.8%	-1.5%	-8.5%
11/10/2021	-3.8%	1.1%	-13.2%
8/5/2021	-5.8%	-8.4%	-5.2%
5/10/2021	2.8%	1.5%	7.7%
2/2/2021	-8.3%	-1.8%	-9.4%
11/10/2020	12.1%	19.0%	22.7%
7/30/2020	15.1%	19.8%	10.6%
4/30/2020	-8.6%	-1.3%	6.1%
SUMMARY STATS
# Positive	10	12	12
# Negative	14	12	12
Median Positive	13.0%	15.7%	11.0%
Median Negative	-7.0%	-7.7%	-11.3%
Max Positive	21.8%	22.3%	32.4%
Max Negative	-22.8%	-18.7%	-32.8%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
12/31/2025	02/05/2026	10-Q
09/30/2025	12/04/2025	10-K
06/30/2025	08/06/2025	10-Q
03/31/2025	05/09/2025	10-Q
12/31/2024	02/10/2025	10-Q
09/30/2024	11/27/2024	10-K
06/30/2024	08/06/2024	10-Q
03/31/2024	05/09/2024	10-Q
12/31/2023	02/08/2024	10-Q
09/30/2023	11/21/2023	10-K
06/30/2023	08/09/2023	10-Q
03/31/2023	05/10/2023	10-Q
12/31/2022	02/09/2023	10-Q
09/30/2022	11/25/2022	10-K
06/30/2022	08/09/2022	10-Q
03/31/2022	05/16/2022	10-Q

Insider Activity

Expand for More

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Marotta, John	President and CEO	Direct	Sell	9122025	29.41	316	9,294	3,116,865	Form
2	Lin, Lawrence Y	EVP, CFO and Treasurer	Direct	Buy	8122025	27.96	2,500	69,900	1,286,523	Form
3	Hughes, Violetta	VP, Chief Accounting Officer	Direct	Sell	2042025	52.97	317	16,791	508,671	Form
4	Zhou, Ginger	SVP and General Manager, Genom	Direct	Buy	2042025	45.88	417	19,132	1,280,786	Form

AZTA Trade Sentinel

Stock Conviction

null

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing AZTA?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What AZTA Makes & Who Pays

TTM figures based on

AZTA Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Azenta (AZTA)

Market Price (3/18/2026): $22.13 | Market Cap: $1.0 BilSector: Health Care | Industry: Life Sciences Tools & Services

Azenta (AZTA)

Market Price (3/18/2026): $22.13Market Cap: $1.0 BilSector: Health CareIndustry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Azenta (AZTA)

Interactive Breakdown

Better Bets vs. Azenta (AZTA)

INDUSTRY: Life Sciences Tools & Services

Higher Rev Chg 3Y Avg | Lower P/S (Values for AZTA: 0.6% | 1.7x)

Higher Rev Chg LTM (Value for AZTA: 2.7%)

Higher Rev Chg 3Y Avg (Value for AZTA: 0.6%)

Higher Op Mgn LTM (Value for AZTA: -2.8%)

Higher CFO/Rev LTM (Value for AZTA: 10.6%)

Higher FCF/Rev LTM (Value for AZTA: 5.2%)

Higher Total Yield (Value for AZTA: -5.7%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for AZTA: 0.6% | 1.7x)

Higher Rev Chg LTM (Value for AZTA: 2.7%)

Higher Rev Chg 3Y Avg (Value for AZTA: 0.6%)

Higher Op Mgn LTM (Value for AZTA: -2.8%)

Higher CFO/Rev LTM (Value for AZTA: 10.6%)

Higher FCF/Rev LTM (Value for AZTA: 5.2%)

Higher Total Yield (Value for AZTA: -5.7%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for AZTA: 0.6% | 1.7x)

Higher Rev Chg LTM (Value for AZTA: 2.7%)

Higher Rev Chg 3Y Avg (Value for AZTA: 0.6%)

Higher Op Mgn LTM (Value for AZTA: -2.8%)

Higher CFO/Rev LTM (Value for AZTA: 10.6%)

Higher FCF/Rev LTM (Value for AZTA: 5.2%)

Higher Total Yield (Value for AZTA: -5.7%)

Best Bets in Health Care

P/EBIT (Value for AZTA: -60.1x)

P/E (Value for AZTA: -17.5x)

Rev Chg 3Y Avg (Value for AZTA: 0.6%)

Rev Chg LTM (Value for AZTA: 2.7%)

Rev Chg Q (Value for AZTA: 0.8%)

FCF/Rev 3Y Avg (Value for AZTA: 4.1%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Market Price (3/18/2026): $22.13 | Market Cap: $1.0 Bil
Sector: Health Care | Industry: Life Sciences Tools & Services

Market Price (3/18/2026): $22.13
Market Cap: $1.0 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services